Regorafenib
- Generic Name
- Regorafenib
- Brand Names
- Stivarga
- Drug Type
- Small Molecule
- Chemical Formula
- C21H15ClF4N4O3
- CAS Number
- 755037-03-7
- Unique Ingredient Identifier
- 24T2A1DOYB
- Background
Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in April 2017.
- Indication
Regorafenib is indicated for the treatment of patients with metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy. Regorafenib is also indicated for the treatment of patients with locally advanced, unresecta...
- Associated Conditions
- Hepatocellular Carcinoma, Metastatic Colorectal Cancer (CRC), Metastatic Gastrointestinal Stromal Tumor (GIST), Locally advanced Gastrointestinal stromal tumor, Unresectable Gastrointestinal stromal tumor
- Associated Therapies
- -
Regorafenib Second Line Treatment of Metastatic or Advanced Upper GI Cancers
- First Posted Date
- 2014-09-16
- Last Posted Date
- 2018-01-11
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 5
- Registration Number
- NCT02241720
- Locations
- 🇺🇸
Huntsman Cancer Institute, Salt Lake City, Utah, United States
Regorafenib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction Who Have Completed Chemoradiation Therapy and Surgery
- First Posted Date
- 2014-09-09
- Last Posted Date
- 2018-10-17
- Lead Sponsor
- Academic and Community Cancer Research United
- Target Recruit Count
- 3
- Registration Number
- NCT02234180
- Locations
- 🇺🇸
Cancer Center of Kansas - Wichita, Wichita, Kansas, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States
Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases
- First Posted Date
- 2014-07-21
- Last Posted Date
- 2023-12-05
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 26
- Registration Number
- NCT02195011
- Locations
- 🇺🇸
Tennessee Oncology PLLC, Nashville, Tennessee, United States
🇺🇸Florida Cancer Specialists - North, Saint Petersburg, Florida, United States
🇺🇸Research Medical Center, Kansas City, Missouri, United States
[18F]FLT-PET as a Predictive Imaging Biomaker of Treatment Responses to Regorafenib
- Conditions
- Interventions
- First Posted Date
- 2014-06-26
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 68
- Registration Number
- NCT02175095
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Songpa, Korea, Republic of
Regorafenib as Single Agent in Patients With Metastatic Colorectal Cancer (mCRC) With Any RAS or BRAF Mutation Previously Treated With FOLFOXIRI Plus Bevacizumab
- First Posted Date
- 2014-06-26
- Last Posted Date
- 2017-08-01
- Target Recruit Count
- 15
- Registration Number
- NCT02175654
- Locations
- 🇪🇸
Spanish Cooperative Group for Digestive Tumour Therapy (TTD), Madrid, Spain
Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable GIST
- Conditions
- Interventions
- First Posted Date
- 2014-06-16
- Last Posted Date
- 2021-06-14
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 14
- Registration Number
- NCT02164240
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Study of Ruxolitinib in Colorectal Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2014-04-22
- Last Posted Date
- 2018-02-13
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 396
- Registration Number
- NCT02119676
Safety Study of Regorafenib With PF-03446962 to Treat Colorectal Cancer
- First Posted Date
- 2014-04-17
- Last Posted Date
- 2019-03-14
- Lead Sponsor
- Duke University
- Target Recruit Count
- 11
- Registration Number
- NCT02116894
- Locations
- 🇺🇸
Duke Cancer Center, Duke University Medical Center, Durham, North Carolina, United States
Single Agent Regorafenib in Refractory Advanced Biliary Cancers
- First Posted Date
- 2014-04-16
- Last Posted Date
- 2021-10-12
- Target Recruit Count
- 39
- Registration Number
- NCT02115542
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
🇺🇸VCU Massey Cancer Center, Richmond, Virginia, United States
Regorafenib in Patients with Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
- First Posted Date
- 2014-03-28
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 38
- Registration Number
- NCT02098538
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States
🇺🇸Memorial Sloan Kettering at Mercy Medical Center, Rockville Centre, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.